Skip to main content

Table 1 Characteristics of incident breast cancers diagnosed during October 2006 through July 2012 at Chris Hani Baragwanath Academic Hospital Breast Clinic, Soweto, South Africa

From: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series

Characteristic Variable completeness (%) Category No. (column % among nonmissing data)
Among all incident breast cancers (N = 1247)
Sex 100 Male 12 (1.0)
Female 1232 (99.0)
Invasiveness in women 100 Non-invasive 19 (1.5)
Invasive 1216 (98.5)
Among invasive incident breast cancers in women (N = 1216)
Ethnicity 99.4 Black 1,092 (90.3)
White 49 (4.1)
Colored 46 (3.8)
Asian 22 (1.8)
Age at diagnosis (years)   <40 182 (15.0)
40–49 290 (23.9)
50–59 310 (25.5)
60–69 221 (18.2)
70–79 147 (12.1)
≥80 66 (5.4)
Year of diagnosis 100 2006–2007 172 (14.1)
2008–2009 431 (35.4)
2010–2012 613 (50.4)
HIV status 69.0 Negative 686 (81.8)
Positive 153 (18.2)
Stage 98.1 I 61 (5.1)
IIA 211 (17.7)
IIB 280 (23.5)
IIIA 148 (12.4)
IIIB-IIIC 385 (32.3)
IV metastases 107 (9.0)
Tumor grade 80.0 1 = Well-differentiated 106 (10.9)
2 = Moderately-differentiated 455 (46.8)
3 = Poorly-differentiated 412 (42.3)
ER 88.2 Negative 376 (35.1)
Positive: of which 696 (64.9)
Positive stain score +1 96
+2 155
+3 445
PR 87.8 Negative 500 (46.9)
Positive, of which: 567 (53.1)
Positive staining score +1 111
+2 163
+3 293
HER2 84.9 Negative, of which: 762 (74.1)
Negative stain score 0 404
+1 142
+2 216
Positive (+3) 267 (26.0)
Subtypes abbreviations: 84.5 Luminal A (ERP and/or PRP, HER2N) 551 (53.7)
Luminal B (ERP and/or PRP, HER2P) 150 (14.6)
HER2P enriched (ERN, PRN, HER2P) 117 (11.04)
Triple negative (ERN, PRN, HER2N) 209 (20.4)
  1. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.
\